How Should Algorithm Validation Be Conducted for Overseas Registration of Artificial Intelligence Medical Devices?

Algorithm validation for overseas registration of artificial intelligence medical devices should begin by confirming whether the software falls within the target market’s medical device regulatory scope, then determining the risk class and registration pathway. The evidence package should demonstrate acceptable performance in the intended-use population and should include algorithm design documentation, dataset descriptions, performance validation reports, subgroup and robustness analyses, clinical evaluation or equivalence justification, cybersecurity and software lifecycle controls, version control, and post-market change management. Regulators focus not on whether artificial intelligence is used, but on the risk of the algorithm output, its interpretability, boundaries of use, and whether the evidence is sufficient to support the product claims.

Published: 2026-07-10 21:11 Updated: 2026-07-10 21:11

This FAQ is based on the Aimeili Registration Practice Question Bank, the Medical Device International Registration Knowledge Base, and public regulatory information. Specific projects should follow the latest requirements of the target country’s regulatory authority and the product documentation.

Key Summary

Algorithm validation for artificial intelligence medical devices is a core technical element of overseas registration and directly affects whether a product can pass review. Companies should first confirm whether the target country regulates artificial intelligence software as a medical device, such as the FDA SaMD classification, the EU MDR, or China NMPA’s classification definition for artificial intelligence medical software. Next, determine the risk level: diagnostic support products are usually Class II or Class IIb and above, while treatment decision products carry higher risk. For the registration pathway, most countries require an algorithm design description, training dataset description, performance validation report, clinical evaluation or equivalence argument, and an update control procedure.

Reusable materials include ISO 13485 quality system documentation, MDSAP certification, and NMPA registration documents if already approved, but these must be translated and localized to the target country’s clinical guidelines and labeling requirements. Common risks include insufficient generalization due to data bias, lack of interpretability in black-box models, and undefined change boundaries for continuous learning. Companies should establish a cross-functional regulatory team early in the project, complete product classification and the applicable standards list first, and then develop a validation plan according to the FDA Guidance on SaMD, the IMDRF framework, or GHWP member country requirements.

Local agents should confirm certificate control, change notification obligations, and post-market performance monitoring responsibilities. For multi-country registration, it is advisable to use one master technical file as the basis and supplement clinical data and localization statements for each country to reduce duplication and deficiency risks.

Applicable Scenarios and Core Questions

Algorithm validation for overseas registration of artificial intelligence medical devices applies to all software products based on machine learning, deep learning, or statistical models, including but not limited to medical imaging diagnostic support, disease risk prediction, treatment plan recommendation, and surgical navigation. The core question is: companies must demonstrate to regulators that the algorithm achieves sufficient performance in the intended-use population and that the risks are acceptable. Algorithm validation includes not only accuracy, sensitivity, and specificity, but also performance across subgroups such as age, sex, ethnicity, and disease subtype, as well as stability when input data quality changes.

In addition, continuously learning algorithms require clear version control and change management processes. Companies often mistakenly believe that translating a domestic performance report is sufficient. In practice, overseas registration requires stronger clinical relevance and external validation, especially because the FDA and EU CE requirements for independent test sets are very strict.

Registration Assessment Logic

• First, determine whether the product is a medical device: Based on the target country’s regulations, such as FDA 21 CFR 820, EU MDR 2017/745, Japan’s Pharmaceutical and Medical Device Act, and Korea’s MFDS rules, review the definition of software as a medical device. If the software independently drives diagnosis or treatment decisions, it is usually a medical device; if it only provides reference information or has no clinical intent, it may not be.
• Second, determine the risk level: The FDA classifies SaMD into Class I, II, and III; the EU CE marking system classifies under Rule 11/12 into Class IIa, IIb, and III; China NMPA manages artificial intelligence medical software under its classification definition. The risk level determines the registration pathway and the level of evidence required.
• Third, assess the reusability of existing documents: For products already registered with NMPA, the algorithm design, training, and validation reports can serve as a basis, but companies must assess whether they meet the target country’s requirements for data sources, population representativeness, and clinical outcomes. For example, the FDA requires U.S. population test data, and the EU CE requires compliance with EU clinical guidelines.
• Fourth, determine the registration pathway: Class II devices usually follow self-declaration for CE or 510(k) for the FDA, while Class III devices require PMA or review by an EU notified body. Finally, confirm local agent and post-market maintenance requirements: all countries require an in-country authorized representative responsible for adverse event reporting and change notifications.

Documentation and Evidence

Core technical documents required for algorithm validation include:

• Algorithm description document: model architecture, training data sources, feature engineering, hyperparameter selection, and related details.
• Dataset description: size, distribution, annotation process, and data cleaning methods for training, validation, and test sets.
• Performance validation report: sensitivity, specificity, ROC AUC, positive predictive value, negative predictive value, and 95% confidence intervals.
• Subgroup analysis: results stratified by age, sex, disease severity, and other relevant factors.
• Robustness testing: stability against image noise, missing data, and adversarial attacks.
• Interpretability analysis: for black-box models, provide feature importance, activation maps, or attribution analysis.
• Clinical evaluation: clinical studies or literature citations equivalent to performance validation; however, the FDA and EU CE usually require at least one prospective clinical study.
• Labels and instructions for use: intended use, indications, contraindications, algorithm update mechanism, and performance claims.
• Quality system: ISO 13485 or MDSAP certificate demonstrating controlled software development lifecycle.
• Post-market plan: performance monitoring, re-evaluation, and adverse event reporting procedures.

Common Errors

• Using third-party public datasets such as ImageNet as the only validation source, ignoring target population specificity.
• Cross-contamination between test and training sets, leading to overestimated performance.
• Failure to conduct subgroup analysis, so poor performance in vulnerable groups remains undisclosed.
• Ignoring the impact of software updates on algorithm performance, especially when continuous learning models lack defined trigger conditions and validation processes.
• Performance claims in labels or instructions inconsistent with validation results, or use of absolute language such as 100% accurate.
• Delaying selection of a local agent, causing registration delays or loss of certificate control.
• Overlooking target country clinical data requirements, for example, China requiring Chinese population data and the United States requiring U.S. population data.

Company Preparation Checklist

• Confirm whether the product is a medical device and determine the risk class in the target country.
• Establish a cross-functional team including regulatory, clinical, algorithm, and quality functions.
• Collect target country regulations, guidelines, and standards, such as IMDRF SaMD, FDA Guidance, and EU MDR.
• Review existing registration documents and assess gaps against the target country.
• Develop an algorithm validation plan, including dataset construction, performance metrics, and clinical evaluation strategy.
• Select qualified data annotation providers and testing laboratories.
• Prepare technical file templates and organize content according to target country requirements.
• Contact a local agent or authorized representative and confirm cooperation terms and scope of responsibility.
• Establish software version management and change control processes.
• Initiate a post-market surveillance plan, including adverse event monitoring and periodic performance review.

Aimeili Perspective

Companies most easily misjudge the situation by assuming that good algorithm performance alone will secure registration in any country. In reality, regulators focus more on whether algorithm performance is stable in the real world and whether software updates introduce new risks. In the early stage, companies should conduct a regulatory gap analysis rather than diving directly into technical development. The most time-efficient approach is to first determine the target country, then find the corresponding standards for gap analysis. NMPA, CE, and FDA technical documents can be partially reused, but clinical data and instructions for use must be localized, especially units of measure, diagnostic thresholds, and reference ranges.

For multi-country registration, it is advisable to use one master technical file as the base and supplement epidemiological data, clinical guideline citations, and translations for each country. A local agent is responsible not only for registration but also for certificate maintenance, change notifications, and renewals. Therefore, a contract with clear rights and responsibilities must be signed, specifying agency fees and certificate control ownership. Post-market maintenance requires continuous investment, and establishing a globally unified adverse event database can save costs. Companies should avoid frequent algorithm updates before registration, otherwise validation may need to be repeated. In summary, the core of algorithm validation is to build a credible evidence chain proving the safety and effectiveness of the software in a specific population.

Common Follow-up Questions

Q1: If my artificial intelligence device is already approved in China, do I still need to redo algorithm validation in the target country?

Re-evaluation is required rather than a complete redo. In NMPA registration documents, the algorithm design, training and validation process, and software architecture can be reused, but test data or clinical studies for the target country population must be added. For example, the FDA usually requires independent validation in the U.S. population, and the EU CE requires EU population data or an equivalence argument. At the same time, technical documents must be translated into the target country language, and clinical reference standards in the instructions for use must be adjusted. Companies should consider a pre-submission meeting with the target country regulator to confirm the acceptability of the documents.

Q2: Must algorithm validation use clinical trial data?

Not necessarily, but in most cases it does. Artificial intelligence devices at Class II risk level and above usually require at least one prospective clinical study or retrospective validation based on real-world data. For lower-risk devices, if there is substantial literature or comparator data for the same type of product, an equivalence argument may be possible. The FDA and EU CE both accept real-world data, such as electronic medical records and image libraries, as supplementary evidence, but data quality, annotation accuracy, and patient privacy compliance must be ensured. The final requirement depends on the product risk level and intended use.

Q3: How should algorithm validation be performed for continuously learning artificial intelligence?

Continuously learning artificial intelligence must have a clearly defined update mechanism, trigger conditions, and validation method in the technical file. Regulators require that after each update, algorithm performance is not lower than the previous version and does not introduce new risks. A common approach is to set performance monitoring indicators, re-validate when post-deployment performance degrades below a threshold, conduct offline testing before updates, and provide a comparison report between old and new versions. All updates must be notified to the regulator or notified body. The FDA has issued guidance frameworks such as the Predetermined Change Control Plan, and companies can develop update processes according to such frameworks.

Implementation Recommendations

Companies should break this issue into five tasks: regulatory assessment, document preparation, evidence reuse, localization conversion, and post-market maintenance, rather than having one department temporarily organize documents. This helps identify document gaps earlier and enables sales, R&D, quality, and regulatory teams to form a consistent understanding of target country requirements.

If a company plans to enter multiple markets simultaneously, it is advisable to first create a unified core technical file and then supplement authorizations, labels, languages, forms, and local agent documents for different countries. The efficiency of multi-country registration often depends on whether the early document framework is unified, rather than how fast a single country submission is.

• First confirm whether the product falls within the target country’s medical device regulatory scope.
• Then confirm the risk class, registration pathway, and applicant entity.
• Check whether technical documents, quality system, and clinical evidence support each other.
• Clarify the local agent, authorized representative, and certificate control ownership.
• Establish post-market change, renewal, and vigilance event maintenance mechanisms.

Additional Execution Points

When handling questions such as how to conduct algorithm validation for overseas registration of artificial intelligence medical devices, companies should manage regulatory assessment, documentary evidence, applicant entity, launch timing, and post-market responsibilities in the same project plan. This prevents the regulatory department from focusing only on documents, the sales department from focusing only on launch timing, and the quality department from not understanding target market requirements, which can ultimately disconnect the registration pathway from document preparation.

If the target market is a GHWP member country or is highly aligned with international rules such as IMDRF, ISO 13485, ISO 14971, and UDI, companies should also prioritize reviewing reusable documents and then decide which content requires localization, supplementary declarations, retesting, or signature by a local agent. This sequence is more stable than directly collecting documents according to a country checklist and makes cost control easier.

At the project execution level, companies should retain at least the product classification basis, technical file versions, label and instructions for use versions, test report model coverage, clinical evidence sources, local agent communication records, and deficiency response records. These records directly affect how quickly a company can explain product compliance status during subsequent renewals, changes, inspections, or post-market event handling.

• Confirm the product intended use and target market regulatory status.
• Confirm the risk class, registration pathway, and applicant entity.
• Confirm whether the core technical file can be reused across markets.
• Confirm localized documents, label language, and authorization documents.
• Confirm post-market surveillance, change, and renewal responsibilities.

Further Reading

• Previous: How Should Technical Documentation Be Prepared for Overseas Registration of Software Medical Devices?
• Next: How Should Southeast Asian Medical Device Registration Dossiers Be Unified?
• Recommended reading: How Should Technical Documentation Be Prepared for Overseas Registration of Software Medical Devices?
• Recommended reading: How Should Southeast Asian Medical Device Registration Dossiers Be Unified?
• Recommended reading: What Are the Risks of Local Agents in Middle East Medical Device Registration?
• Recommended reading: Why Are Medical Device Registration Timelines Often Extended in Latin America?
• Recommended reading: How Should Product Classification Be Determined for Overseas Medical Device Registration?
• Recommended reading: What Should Be Done When Quality System Evidence Is Inconsistent for Overseas Medical Device Registration?
• Return to FAQ Center
• News and Information
• Contact Aimeili

Content Review and Applicability Boundaries

• Content author: Aimeili Regulatory Editorial Team
• Professional review: Aimeili Medical Device International Registration Project Team
• Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory information; industry media and project experience are used only as auxiliary judgment.
• Applicability boundaries: This article is for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target country’s regulatory authority, testing conclusions, or legal advice.